Ovid Therapeutics (OVID) Operating Leases (2022 - 2026)

Ovid Therapeutics (OVID) has reported Operating Leases for 5 consecutive years, with $11.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 11.67% year-over-year to $11.2 million; the trailing twelve-month figure through Jun 2026 stood at $11.2 million (down 11.67% YoY), and the FY2025 full-year result was $12.0 million, down 10.68% from the prior year.
• Operating Leases declined to $11.2 million in Q2 2026 per OVID's latest filing, from $11.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $16.2 million in Q3 2022 and bottomed at $11.2 million in Q2 2026.
• Historically, Operating Leases has averaged $14.1 million across 5 years, with a median of $14.3 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Operating Leases declined 1.09% in 2023, then retreated 11.67% in 2026.
• Over 5 years, Operating Leases stood at $16.0 million in 2022, then retreated by 7.78% to $14.8 million in 2023, then dropped by 9.06% to $13.4 million in 2024, then fell by 10.68% to $12.0 million in 2025, then decreased by 6.3% to $11.2 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $11.2 million, $11.6 million, and $12.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.